Targeting natural killer cells in cancer immunotherapy

Nature Immunology

Volumn 17, Issue 9, 2016, Pages 1025-1036

  Guillerey, Camille ^a,b   Huntington, Nicholas D ^c,d   Smyth, Mark J ^a,b,d  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; INTERLEUKIN 15; NATURAL KILLER CELL RECEPTOR; NECTIN 2; TRANSCRIPTION FACTOR LHX3; CYTOKINE; EOMES PROTEIN, HUMAN; EOMES PROTEIN, MOUSE; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; T BOX TRANSCRIPTION FACTOR; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NATURAL KILLER CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL; TUMOR MICROENVIRONMENT; ADVERSE EFFECTS; ANIMAL; CYTOTOXICITY; FORECASTING; GRAFT VS HOST DISEASE; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INNATE IMMUNITY; MOUSE; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SECRETION (PROCESS); TRANSPLANTATION; TUMOR ESCAPE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FORECASTING; GRAFT VS HOST DISEASE; HUMANS; IMMUNITY, INNATE; IMMUNOPHENOTYPING; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-15; KILLER CELLS, NATURAL; MICE; NEOPLASMS; RECEPTORS, NATURAL KILLER CELL; RECOMBINANT FUSION PROTEINS; T-BOX DOMAIN PROTEINS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84983343680     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3518     Document Type: Review

References (144)

1. Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. Functions of natural killer cells. Nat. Immunol. 9, 503-510 (2008
2. Huntington, N.D., Vosshenrich, C.A., & Di Santo, J.P. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat. Rev. Immunol. 7, 703-714 (2007
3. Hayakawa, Y., Huntington, N.D., Nutt, S.L., & Smyth, M.J. Functional subsets of mouse natural killer cells. Immunol. Rev. 214, 47-55 (2006
4. Martinet, L. et al. DNAM-1 expression marks an alternative program of NK cell maturation. Cell Rep. 11, 85-97 (2015
5. Sojka, D.K., Tian, Z., & Yokoyama, W.M. Tissue-resident natural killer cells and their potential diversity. Semin. Immunol. 26, 127-131 (2014
6. Cortez, V.S., Fuchs, A., Cella, M., Gilfillan, S., & Colonna, M. Cutting edge: Salivary gland NK cells develop independently of Nfil3 in steady-state. J. Immunol. 192, 4487-4491 (2014
7. Marquardt, N. et al. Cutting edge: identification and characterization of human intrahepatic CD49a+ NK cells. J. Immunol. 194, 2467-2471 (2015
8. Spits, H. et al. Innate lymphoid cells-A proposal for uniform nomenclature. Nat. Rev. Immunol. 13, 145-149 (2013
9. Raulet, D.H., & Vance, R.E. Self-Tolerance of natural killer cells. Nat. Rev. Immunol. 6, 520-531 (2006
10. Romee, R., Leong, J.W., & Fehniger, T.A. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo) 2014, 205796 (2014
11. Guillerey, C. et al. Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis. OncoImmunology 4, e1027468 (2015
12. Voskoboinik, I., Smyth, M.J., & Trapani, J.A. Perforin-mediated target-cell death and immune homeostasis. Nat. Rev. Immunol. 6, 940-952 (2006
13. Sungur, C.M., & Murphy, W.J. Positive and negative regulation by NK cells in cancer. Crit. Rev. Oncog. 19, 57-66 (2014
14. Iannello, A., Thompson, T.W., Ardolino, M., Lowe, S.W., & Raulet, D.H. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J. Exp. Med. 210, 2057-2069 (2013
15. Guillerey, C., & Smyth, M.J. NK cells and cancer immunoediting. Curr. Top. Microbiol. Immunol. 395, 115-145 (2016
16. Vitale, M., Cantoni, C., Pietra, G., Mingari, M.C., & Moretta, L. Effect of tumor cells and tumor microenvironment on NK-cell function. Eur. J. Immunol. 44, 1582-1592 (2014
17. Krasnova, Y., Putz, E.M., Smyth, M.J., & Souza-Fonseca-Guimaraes, F. Bench to bedside: NK cells and control of metastasis. Clin. Immunol. S1521-6616(15)30050-4 (2015
18. Ghiringhelli, F. et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J. Exp. Med. 202, 1075-1085 (2005
19. Smyth, M.J. et al. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176, 1582-1587 (2006
20. Beavis, P.A. et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc. Natl. Acad. Sci. USA 110, 14711-14716 (2013
21. Mittal, D. et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 74, 3652-3658 (2014
22. Stacey, M.A., Marsden, M., Wang, E.C., Wilkinson, G.W., & Humphreys, I.R. IL-10 restricts activation-induced death of NK cells during acute murine cytomegalovirus infection. J. Immunol. 187, 2944-2952 (2011
23. Mocellin, S. et al. IL-10 stimulatory effects on human NK cells explored by gene profile analysis. Genes Immun. 5, 621-630 (2004
24. Viel, S. et al. TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal. 9, ra19 (2016
25. Sconocchia, G. et al. Melanoma cells inhibit NK cell functions. Cancer Res. 72, 5428-5429 author reply 5430 (2012
26. Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097-2100 (2002
27. Benson, D.M. Jr. et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 118, 6387-6391 (2011
28. Grossenbacher, S.K., Canter, R.J., & Murphy, W.J. Natural killer cell immunotherapy to target stem-like tumor cells. J. Immunother. Cancer 4, 19 (2016
29. Delgado, D.C. et al. Genotypes of NK cell KIR receptors, their ligands, and Fc? receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 70, 9554-9561 (2010
30. Yang, R.K. et al. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival. Cancer Immunol. Immunother. 62, 1303-1313 (2013
31. Han, J. et al. CAR-engineered NK cells targeting wild-Type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci. Rep. 5, 11483 (2015
32. Zhang, C. et al. ErbB2/HER2-specific NK cells for targeted therapy of glioblastoma. J. Natl. Cancer Inst. 108, djv375 (2015
33. Genßler, S. et al. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. OncoImmunology 5, e1119354 (2015
34. Besse, B. et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. OncoImmunology 5, e1071008 (2015
35. Tonn, T. et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 15, 1563-1570 (2013
36. Becker, P.S. et al. Selection and expansion of natural killer cells for NK cell-based immunotherapy. Cancer Immunol. Immunother. 65, 477-484 (2016
37. Knorr, D.A., Bachanova, V., Verneris, M.R., & Miller, J.S. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin. Immunol. 26, 161-172 (2014
38. Rueff, J., Medinger, M., Heim, D., Passweg, J., & Stern, M. Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma. Biol. Blood Marrow Transplant. 20, 896-899 (2014
39. Porrata, L.F. et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol. Blood Marrow Transplant. 14, 807-816 (2008
40. Sakamoto, N. et al. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J. Transl. Med. 13, 277 (2015).
41. Parkhurst, M.R., Riley, J.P., Dudley, M.E., & Rosenberg, S.A. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin. Cancer Res. 17, 6287-6297 (2011
42. Curti, A. et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118, 3273-3279 (2011
43. Miller, J.S. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051-3057 (2005
44. Rubnitz, J.E. et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J. Clin. Oncol. 28, 955-959 (2010
45. Shah, N.N. et al. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood 125, 784-792 (2015
46. Bishara, A. et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-Alloreactive T cells causing GVHD. Tissue Antigens 63, 204-211 (2004
47. Davies, S.M. et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100, 3825-3827 (2002
48. Gill, S., & June, C.H. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol. Rev. 263, 68-89 (2015
49. Klingemann, H. Are natural killer cells superior CAR drivers?. OncoImmunology 3, e28147 (2014
50. Glienke, W. et al. Advantages and applications of CAR-expressing natural killer cells. Front. Pharmacol. 6, 21 (2015
51. Klingemann, H. Challenges of cancer therapy with natural killer cells. Cytotherapy 17, 245-249 (2015
52. Romanski, A. et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J. Cell. Mol. Med. 20, 1287-1294 (2016
53. Schönfeld, K. et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol. Ther. 23, 330-338 (2015).
54. Leong, J.W. et al. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-Affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol. Blood Marrow Transplant. 20, 463-473 (2014
55. Burns, L.J. et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant. 32, 177-186 (2003
56. Bachanova, V. et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123, 3855-3863 (2014).
57. Steele, N. et al. A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer. Br. J. Cancer 106, 793-798 (2012
58. Waldmann, T.A. Interleukin-15 in the treatment of cancer. Expert Rev. Clin. Immunol. 10, 1689-1701 (2014
59. Porrata, L.F. et al. Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas. Clin. Dev. Immunol. 2010, 914945 (2010
60. Conlon, K.C. et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33, 74-82 (2015).
61. Pérez-Martínez, A. et al. A phase I/II trial of interleukin-15-stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. Cytotherapy 17, 1594-1603 (2015
62. Kim, P.S. et al. IL-15 superagonist/IL-15R?Sushi-Fc fusion complex (IL-15SA/IL-15R?Su-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-Tumor activity against murine breast and colon carcinomas. Oncotarget 7, 16130-16145 (2016
63. Sahm, C., Schönfeld, K., & Wels, W.S. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol. Immunother. 61, 1451-1461 (2012
64. Imamura, M. et al. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood 124, 1081-1088 (2014
65. Krieg, S., & Ullrich, E. Novel immune modulators used in hematology: impact on NK cells. Front. Immunol. 3, 388 (2013
66. Davies, F.E. et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98, 210-216 (2001
67. Borg, C. et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 114, 379-388 (2004
68. Parameswaran, R. et al. Repression of GSK3 restores NK cell cytotoxicity in AML patients. Nat. Commun. 7, 11154 (2016).
69. Schmiedel, B.J. et al. Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int. J. Cancer 128, 2911-2922 (2011
70. Rossi, L.E. et al. Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression. J. Leukoc. Biol. 91, 321-331 (2012
71. Jardine, L. et al. Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands. Leuk. Lymphoma 54, 167-173 (2013
72. Wang, X. et al. Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity. Haematologica 94, 470-478 (2009
73. Lundqvist, A., Yokoyama, H., Smith, A., Berg, M., & Childs, R. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood 113, 6120-6127 (2009
74. Marçais, A. et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat. Immunol. 15, 749-757 (2014
75. Weiner, L.M., Surana, R., & Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10, 317-327 (2010
76. Bakema, J.E., & Van Egmond, M. Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer. Curr. Top. Microbiol. Immunol. 382, 373-392 (2014
77. Weng, W.K., & Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21, 3940-3947 (2003
78. Rodríguez, J. et al. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. Eur. J. Cancer 48, 1774-1780 (2012
79. Clynes, R.A., Towers, T.L., Presta, L.G., & Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6, 443-446 (2000
80. Gluck, W.L. et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkins lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin. Cancer Res. 10, 2253-2264 (2004
81. Romee, R. et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 121, 3599-3608 (2013
82. Zhou, Q., Gil-Krzewska, A., Peruzzi, G., & Borrego, F. Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-Tumour immunotherapy. Clin. Exp. Immunol. 173, 131-139 (2013
83. Bowles, J.A. et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108, 2648-2654 (2006
84. Gerdes, C.A. et al. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin. Cancer Res. 19, 1126-1138 (2013
85. Roberti, M.P. et al. IL-2-or IL-15-Activated NK cells enhance cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients. Breast Cancer Res. Treat. 136, 659-671 (2012
86. Moga, E. et al. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp. Hematol. 36, 69-77 (2008
87. Wu, L. et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-Treated CD20+ tumor cells. Clin. Cancer Res. 14, 4650-4657 (2008
88. Gleason, M.K. et al. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol. Cancer Ther. 11, 2674-2684 (2012
89. Hartmann, F. et al. Treatment of refractory Hodgkins disease with an anti-CD16/CD30 bispecific antibody. Blood 89, 2042-2047 (1997
90. Shahied, L.S. et al. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J. Biol. Chem. 279, 53907-53914 (2004
91. Wiernik, A. et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin. Cancer Res. 19, 3844-3855 (2013
92. Schmohl, J.U., Gleason, M.K., Dougherty, P.R., Miller, J.S., & Vallera, D.A. Heterodimeric bispecific single chain variable fragments (scFv) killer engagers (BiKEs) enhance NK-cell activity against CD133+ colorectal cancer cells. Target. Oncol. (2015).
93. Vallera, D.A. et al. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to cd33+ targets while also inducing persistence, in vivo expansion, and enhanced function. Clin. Cancer Res. (2016).
94. Boltz, A. et al. Bi-specific aptamers mediating tumor cell lysis. J. Biol. Chem. 286, 21896-21905 (2011
95. Kellner, C. et al. Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity. Leukemia 26, 830-834 (2012
96. von Strandmann, E.P. et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 107, 1955-1962 (2006
97. Groh, V., Wu, J., Yee, C., & Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734-738 (2002
98. Deng, W. et al. Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science 348, 136-139 (2015).
99. Lanier, L.L. NKG2D receptor and its ligands in host defense. Cancer Immunol. Res. 3, 575-582 (2015
100. Raulet, D.H., Gasser, S., Gowen, B.G., Deng, W., & Jung, H. Regulation of ligands for the NKG2D activating receptor. Annu. Rev. Immunol. 31, 413-441 (2013
101. Delahaye, N.F. et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat. Med. 17, 700-707 (2011
102. Semeraro, M. et al. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci. Transl. Med. 7, 283ra55 (2015
103. Viaud, S. et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One 4, e4942 (2009
104. Guillerey, C. et al. Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J. Clin. Invest. 125, 2077-2089 (2015
105. Chan, C.J. et al. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J. Immunol. 184, 902-911 (2010
106. Makkouk, A., Chester, C., & Kohrt, H.E. Rationale for anti-CD137 cancer immunotherapy. Eur. J. Cancer 54, 112-119 (2016
107. Baessler, T. et al. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 115, 3058-3069 (2010
108. Kohrt, H.E. et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117, 2423-2432 (2011
109. Kohrt, H.E. et al. Targeting CD137 enhances the efficacy of cetuximab. J. Clin. Invest. 124, 2668-2682 (2014).
110. Sanmamed, M.F. et al. Agonists of co-stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin. Oncol. 42, 640-655 (2015
111. Romagné, F. et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 114, 2667-2677 (2009
112. Benson, D.M. Jr. et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 120, 4324-4333 (2012
113. Vey, N. et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 120, 4317-4323 (2012).
114. Korde, N. et al. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica 99, e81-e83 (2014
115. Kohrt, H.E. et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123, 678-686 (2014
116. Wieten, L., Mahaweni, N.M., Voorter, C.E., Bos, G.M., & Tilanus, M.G. Clinical and immunological significance of HLA-E in stem cell transplantation and cancer. Tissue Antigens 84, 523-535 (2014
117. Nguyen, S. et al. HLA-E upregulation on IFN-?-Activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT. Bone Marrow Transplant. 43, 693-699 (2009
118. Martinet, L., & Smyth, M.J. Balancing natural killer cell activation through paired receptors. Nat. Rev. Immunol. 15, 243-254 (2015
119. Chan, C.J. et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat. Immunol. 15, 431-438 (2014
120. Blake, S.J. et al. Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer Discov. 6, 446-459 (2016).
121. Lesokhin, A.M., Callahan, M.K., Postow, M.A., & Wolchok, J.D. On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci. Transl. Med. 7, 280sr1 (2015
122. Stojanovic, A., Fiegler, N., Brunner-Weinzierl, M., & Cerwenka, A. CTLA-4 is expressed by activated mouse NK cells and inhibits NK Cell IFN-? production in response to mature dendritic cells. J. Immunol. 192, 4184-4191 (2014
123. Huang, B.Y. et al. The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells. PLoS One 10, e0134715 (2015
124. Westin, J.R. et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 15, 69-77 (2014
125. da Silva, I.P. et al. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol. Res. 2, 410-422 (2014
126. Xu, L. et al. Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int. Immunopharmacol. 29, 635-641 (2015
127. Wang, Z. et al. The clinical significance of abnormal Tim-3 expression on NK cells from patients with gastric cancer. Immunol. Invest. 44, 578-589 (2015
128. Nowak, J. et al. role of donor activating KIR-HLA ligand-mediated NK cell education status in control of malignancy in hematopoietic cell transplant recipients. Biol. Blood Marrow Transplant. 21, 829-839 (2015
129. Tarek, N. et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J. Clin. Invest. 122, 3260-3270 (2012
130. Zamora, A.E., Grossenbacher, S.K., Aguilar, E.G., & Murphy, W.J. Models to study NK cell biology and possible clinical application. Curr. Protoc. Immunol. 110, 11-14 (2015
131. Huntington, N.D., Mention, J., Vosshenrich, C.A., Satoh-Takayama, N., & Di Santo, J.P. in Natural Killer Cells-At the Forefront of Modern Immunology 39-61 (Springer, 2010
132. Li, Y., & Di Santo, J.P. Probing human NK cell biology using human immune system (HIS) mice. Curr. Top. Microbiol. Immunol. 395, 191-208 (2016
133. Paolino, M. et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature 507, 508-512 (2014).
134. Putz, E.M. et al. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep. 4, 437-444 (2013
135. Delconte, R.B. et al. CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nat. Immunol. 17, 816-824 (2016).
136. Maghazachi, A.A. Role of chemokines in the biology of natural killer cells. Curr. Top. Microbiol. Immunol. 341, 37-58 (2010
137. Bernardini, G., & Santoni, A. The pathophysiological role of chemokines in the regulation of NK cell tissue homing. Crit. Rev. Oncog. 19, 77-90 (2014
138. Young, A., Mittal, D., Stagg, J., & Smyth, M.J. Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov. 4, 879-888 (2014
139. Huntington, N.D. The unconventional expression of IL-15 and its role in NK cell homeostasis. Immunol. Cell Biol. 92, 210-213 (2014
140. Delconte, R.B. et al. The helix-loop-helix protein ID2 governs NK cell fate by tuning their sensitivity to interleukin-15. Immunity 44, 103-115 (2016
141. Stanietsky, N. et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc. Natl. Acad. Sci. USA 106, 17858-17863 (2009
142. Stanietsky, N. et al. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur. J. Immunol. 43, 2138-2150 (2013
143. Fuchs, A., Cella, M., Giurisato, E., Shaw, A.S., & Colonna, M. Cutting edge: CD96 (tactile) promotes NK cell-Target cell adhesion by interacting with the poliovirus receptor (CD155). J. Immunol. 172, 3994-3998 (2004
144. Jones, B.S., Lamb, L.S., Goldman, F., & Di Stasi, A. Improving the safety of cell therapy products by suicide gene transfer. Front. Pharmacol. 5, 254 (2014